5-Amino-1MQ vs Tesofensine: Oral, Non-GLP-1 Metabolic Research Compounds Compared
5-Amino-1MQ inhibits the NNMT enzyme in rodent studies; Tesofensine reached Phase 2 human trials as a triple monoamine reuptake inhibitor for weight loss.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
5-Amino-1MQ and Tesofensine are two of the most frequently searched non-GLP-1 metabolic research compounds, and researchers increasingly want to know how their mechanisms diverge from the incretin pathway that dominates the category. Both are studied for effects on body weight and adiposity, but they act through entirely unrelated systems — one through enzyme inhibition inside the adipocyte, the other through monoamine transporter blockade in the central nervous system — and they sit at very different points in the evidence pipeline.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: 5-Amino-1MQ is a small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor studied only in cell culture and rodent models, while Tesofensine is a triple monoamine reuptake inhibitor that reached Phase 2 human trials before its original obesity program was discontinued. Researchers select between them based on whether the study question is peripheral adipocyte metabolism or central appetite and reward circuitry.
TL;DR:
- 5-Amino-1MQ inhibits NNMT, raising intracellular NAD+ and SAM and reducing body weight in diet-induced obese mice; no published human trial data exist.
- Tesofensine blocks reuptake at the dopamine, serotonin, and norepinephrine transporters and produced measurable weight reduction in a Phase 2 trial before its original program was discontinued.
- Evidence stage differs sharply: 5-Amino-1MQ is preclinical-only; Tesofensine has human pharmacodynamic and structural data.
- Neither compound is FDA approved, and neither carries a finalized 503A or 503B compounding designation.
- Both are studied as alternatives to GLP-1 receptor agonism rather than as head-to-head competitors with each other.
5-Amino-1MQ: mechanism and evidence base
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule, membrane-permeable inhibitor of nicotinamide N-methyltransferase, an enzyme expressed at high levels in white adipose tissue and liver. NNMT transfers a methyl group from S-adenosyl-methionine to nicotinamide, generating 1-methylnicotinamide. Investigators studying NNMT inhibition proposed that blocking this reaction shifts cellular energy metabolism by increasing the intracellular pool of NAD+ and SAM available for other processes (PMID 29155147).
In the foundational report on this compound class, methylquinolinium analogues were characterized for membrane permeability and selectivity against related methyltransferases and NAD+ salvage-pathway enzymes before being tested in cultured adipocytes and in vivo. In 3T3-L1 adipocytes, 5-Amino-1MQ reduced intracellular 1-methylnicotinamide, raised NAD+ and SAM levels, and suppressed lipogenesis. In diet-induced obese mice, eleven days of systemic dosing reduced body weight, white adipose mass, and adipocyte size, and lowered plasma total cholesterol, without a corresponding change in total food intake or any observable adverse effects reported by the investigators (PMID 29155147).
That absence of an appetite-suppression signal is mechanistically notable: it suggests the weight and adiposity effects observed in this model arise from altered adipocyte energy handling rather than reduced caloric intake, distinguishing the proposed mechanism from centrally acting compounds. As of this writing, all published data on 5-Amino-1MQ remain preclinical — cell culture and rodent studies only. No peer-reviewed human efficacy or safety trial has been published, and the compound holds no FDA approval of any kind.
Tesofensine: mechanism and evidence base
Tesofensine is a triple monoamine reuptake inhibitor that simultaneously blocks reuptake at the dopamine transporter (DAT), the serotonin transporter (SERT), and the norepinephrine transporter (NET). Structural work resolving an ensemble of DAT conformations bound to five distinct triple reuptake inhibitors found that tesofensine, together with dasotraline, stabilizes DAT in an outward-facing conformation — in contrast to compounds such as centanafadine, ansofaxine, and nefazodone, which captured an inward-facing state (PMID 41392177). That conformational preference is one proposed structural explanation for the compound's binding affinity and functional duration relative to its plasma exposure.
Unlike 5-Amino-1MQ, tesofensine's research history includes human trial data. A Phase 2 randomized trial (Astrup et al., Lancet 2008) reported dose-dependent weight reduction over 24 weeks of treatment relative to placebo, and the compound's pharmacology was originally developed in the context of depression and neurodegenerative disease research before its metabolic effects were characterized. Because tesofensine acts on three separate monoamine systems rather than a single peripheral enzyme, researchers have used it as a comparator for questions about central appetite and reward-circuit involvement in weight regulation, distinct from the incretin-receptor mechanisms of GLP-1 agonists. Tesofensine's original obesity development program was subsequently discontinued, and it currently holds no FDA approval for any indication; it remains an investigational compound used in structural and pharmacological research contexts.
Side-by-side comparison
| 5-Amino-1MQ | Tesofensine | |
|---|---|---|
| Primary mechanism | NNMT enzyme inhibition (peripheral, adipocyte) | Triple monoamine reuptake inhibition — DAT/SERT/NET (central) |
| Molecule class | Small-molecule methylquinolinium compound | Small-molecule triple reuptake inhibitor |
| Route studied | Systemic dosing, rodent models | Oral, human Phase 2 trial |
| Evidence stage | Preclinical only (cell culture, rodent) | Phase 2 human data; structural biology data |
| Reported effect on intake | No change in total food intake reported | Central appetite/reward pathway implicated |
| Regulatory status | Not FDA approved; no 503A/503B designation | Not FDA approved; original program discontinued |
| Primary citation | PMID 29155147 | PMID 41392177 |
Differential research applications
Researchers choose between these two compounds based on the biological question, not comparative efficacy, since no published study has directly compared them. A study focused on peripheral adipocyte energy metabolism, NAD+ salvage pathway crosstalk, or lipogenesis suppression independent of caloric restriction is more likely to use an NNMT-inhibition model like 5-Amino-1MQ, given the reported absence of a feeding-behavior confound in the diet-induced obesity data. A study focused on central appetite regulation, dopaminergic reward signaling, or monoamine transporter pharmacology — including comparisons with SSRIs or SNRIs — is more likely to reference tesofensine's transporter-binding and Phase 2 pharmacodynamic profile.
Both compounds are also frequently discussed as non-incretin alternatives in the broader "GLP-1 alternative" research literature, alongside semaglutide and other incretin-pathway agonists, precisely because they represent mechanistically distinct approaches to the same downstream outcome — body weight reduction — without engaging the GLP-1 receptor. Researchers comparing evidence maturity across mechanism classes can cross-reference trial-phase and citation-count data for both compounds and their incretin-pathway counterparts using the site's evidence explorer tool.
This mechanism-first framing also matters for study design. Because 5-Amino-1MQ's rodent data show no measurable change in food intake alongside reduced adiposity, a researcher isolating peripheral energy-handling variables from behavioral feeding variables may prefer it as a cleaner model for that specific question, even though its evidence base is earlier-stage. Conversely, because tesofensine's mechanism runs through reward and appetite circuitry with published human pharmacodynamic data, it is the more appropriate reference compound for questions that require translational or clinical-stage evidence, such as dose-response modeling or comparison against approved centrally-acting agents. Neither compound's research program is positioned to directly displace incretin-pathway agonists as a category; both instead occupy adjacent mechanism niches that the current GLP-1 and dual/triple-agonist literature does not address.
Regulatory and compounding status
Neither compound is FDA approved. 5-Amino-1MQ has not appeared on any FDA 503A or 503B nominations list reviewed by the Pharmacy Compounding Advisory Committee (PCAC) as of this writing, and its evidence base remains too early-stage (preclinical only) to support a compounding nomination in the near term. Tesofensine likewise carries no FDA approval; its original obesity development program was discontinued following the Phase 2 readout, and it has not been the subject of a 503A or 503B compounding petition. Researchers tracking PCAC review status for compounds in this category can monitor upcoming hearings through the site's compounding review resources.
Cited studies
- PMID 29155147 — "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice" (2018). https://doi.org/10.1016/j.bcp.2017.11.007
- PMID 41392177 — "Structural basis for pharmacotherapeutic action of triple reuptake inhibitors" (2008). https://doi.org/10.1016/S0140-6736(08)61525-1
Frequently asked questions
Q: Is 5-Amino-1MQ a peptide?
A: No. 5-Amino-1MQ is a small-molecule methylquinolinium compound, not a peptide, but it is frequently discussed alongside metabolic research peptides because it targets the same broad research question — body weight and adiposity regulation — through a distinct enzymatic mechanism (NNMT inhibition).
Q: Has tesofensine been tested in humans?
A: Yes. A Phase 2 randomized trial (Astrup et al., Lancet 2008) evaluated tesofensine for weight reduction over 24 weeks and reported a dose-dependent effect relative to placebo. Its original obesity development program was later discontinued, and structural biology work has since characterized its transporter-binding mechanism in further detail.
Q: Why compare an NNMT inhibitor to a monoamine reuptake inhibitor?
A: Both are studied as non-GLP-1 approaches to metabolic and weight research, but they act through unrelated systems — one peripheral and enzymatic, the other central and transporter-based. Comparing them helps researchers frame study questions around mechanism class rather than assuming all non-incretin compounds behave similarly.
Q: Does 5-Amino-1MQ suppress appetite like tesofensine?
A: The published diet-induced obesity data for 5-Amino-1MQ reported no change in total food intake despite reduced body weight and adipose mass, suggesting a metabolic rather than appetite-suppression mechanism. Tesofensine's monoamine mechanism, by contrast, is more directly linked to central appetite and reward circuitry in the research literature.
Q: Are either of these compounds FDA approved or available for compounding?
A: Neither compound is FDA approved for any indication. Neither has a finalized 503A or 503B compounding bulk substances designation, and both remain investigational research compounds only.
See also:
- Tesofensine vs Semaglutide: Oral Monoamine vs GLP-1 Mechanisms Compared — direct comparison of tesofensine against the leading incretin-pathway compound.
- 5-Amino-1MQ and NNMT Inhibition: Metabolic Research Overview — standalone profile covering the NNMT mechanism in more depth.
- Best Peptides for Weight Loss Research: 9 Compounds Ranked — broader category context for where non-GLP-1 compounds fit among ranked metabolic research candidates.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.